Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden.
J Mol Biol. 2011 May 13;408(4):684-96. doi: 10.1016/j.jmb.2011.02.059. Epub 2011 Mar 17.
Cytosolic 5'-nucleotidase II (cN-II) catalyzes the dephosphorylation of 6-hydroxypurine nucleoside 5'-monophosphates and participates in the regulation of purine nucleotide pools within the cell. It interferes with the phosphorylation-dependent activation of nucleoside analogues used in the treatment of cancer and viral diseases. It is allosterically activated by a number of phosphate-containing cellular metabolites such as ATP, diadenosine polyphosphates, and 2,3-bisphosphoglycerate, which couple its activity with the metabolic state of the cell. We present seven high-resolution structures of human cN-II, including a ligand-free form and complexes with various substrates and effectors. These structures reveal the structural basis for the allosteric activation of cN-II, uncovering a mechanism where an effector-induced disorder-to-order transition generates rearrangements within the catalytic site and the subsequent coordination of the catalytically essential magnesium. Central to the activation is the large transition of the catalytically essential Asp356. This study also provides the structural basis for the substrate specificity of cN-II, where Arg202, Asp206, and Phe157 seem to be important residues for purine/pyrimidine selectivity. These structures provide a comprehensive structural basis for the design of cN-II inhibitors. They also contribute to the understanding of how the nucleotide salvage pathway is regulated at a molecular level.
细胞质 5'-核苷酸酶 II(cN-II)催化 6-羟嘌呤核苷 5'-单磷酸的去磷酸化,并参与细胞内嘌呤核苷酸池的调节。它干扰用于治疗癌症和病毒病的核苷类似物的磷酸化依赖性激活。它被许多含磷的细胞代谢物别构激活,如 ATP、二腺苷多磷酸和 2,3-二磷酸甘油酸,这使其活性与细胞的代谢状态相偶联。我们展示了七种人源 cN-II 的高分辨率结构,包括无配体形式和与各种底物和效应物的复合物。这些结构揭示了 cN-II 的别构激活的结构基础,揭示了一种效应物诱导的无序到有序的转变产生催化位点内重排,随后催化必需的镁配位的机制。激活的核心是催化必需的 Asp356 的大转变。这项研究还为 cN-II 的底物特异性提供了结构基础,其中 Arg202、Asp206 和 Phe157 似乎是嘌呤/嘧啶选择性的重要残基。这些结构为 cN-II 抑制剂的设计提供了全面的结构基础。它们也有助于理解核苷酸补救途径如何在分子水平上受到调节。